Monsanto Company (NYSE:MON) recorded a trading volume of 1.16 million shares, below its 90-day volume average of 2.15 million shares. The stock kicked off the session at $118.33 and later approached $118.33 with a change of -0.23%.

Monsanto Company (MON) Analyst Opinion

Monsanto Company has a consensus outperform rating from 17 Wall Street analysts, and the number of shares currently sold short amount to at least 0.58% of shares outstanding. The stock sank -3.03% last month and is up 12.47 this year. Wall Street is only getting more bullish on the stock, with 6 of analysts who cover MON having a buy-equivalent rating. Analysts have placed a $125.13 price target on Monsanto Company, suggesting a 5.75% gain from recent close. It’s currently trading about -3.64% below its 52-week high.

Monsanto Company Earnings Surprise

Monsanto Company (MON) surprised the stock market in its last reported earnings when it earned $0.2 a piece versus the consensus-estimated -$0.41. Its revenue totaled $2.53 billion down -40.08% from the previous quarter.

Monsanto Company (NYSE:MON) Intraday View

This stock (MON) is ahead of its 52-week low with 18.03%. Its last month’s stock price volatility remained 0.65% which for the week stands at 0.64%. The share price has moved backward from its 20 days moving average, trading at a distance of -1.33% and stays -1.21% away from its 50 days moving average. Over the last five days, shares have managed 0.03% gains and now is up 1.42% since hitting its 200-day moving average of $118.08. Monsanto Company (MON) has made its way to a 12-month gain of 17.55%.

Turning to Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), its shares were trading at $9.54 a gain of $0.06, on the trading floor. The stock, after opening at $9.37, touched a high of $9.9 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.2. Dicerna Pharmaceuticals, Inc. has 1 buy ratings, 2 holds and 0 sells even after the stock tumbled -2.95% from its high of $9.83 to a $198.43 million market value through last close.

Dicerna Pharmaceuticals, Inc. (DRNA) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 2.2 to 2.2 during a month. Analysts set a 12-month price target of $7.75 a share. The target implies a -18.76% decrease from where the shares are currently trading. Also, the current price highlights a discount of 4.82% to analysts’ high consensus price target.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Intraday Trading

The counter witnessed a trading volume of 0.29 million shares versus an average volume of 0.25 million shares during last trading session. Its last month’s stock price volatility remained 10.58% which for the week approaches 8.99%. The lowest price the stock reached in the last trading day was $9.25 and compares with the $2.42 52-week low. The stock recovered 294.05% since its low point and has performed 231.25% year-to-date.

SHARE
Previous articleLatest Analysts Research Reports About Prudential plc (PUK), Kadmon Holdings, Inc. (KDMN)
Next articleAnalysts Are Gushing Over Novartis AG (NVS), Athersys, Inc. (ATHX)